← Eichor
Study identifier: NCT03262259 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluation of Global Smart Drinking Goals Initiative

Condition: Binge Drinking, Underage Drinking, Drinking and Driving, Alcohol-Related Harms  ·  Sponsor: HBSA

PhaseNA
Planned participants36000
Who can joinAll sexes, 12 Years to no upper limit
Healthy volunteersYes

About this study

This study will evaluate effects of a multi-component, population-level intervention on alcohol use and related harms in six intervention cities relative to six matched comparison cities. Intervention components include screening and brief interventions by health providers, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation. Key outcomes of interest include alcohol-related harms such as alcohol-related motor vehicle crashes and fatalities, heavy/binge drinking, underage drinking, and drinking and driving.

This description comes directly from the study's public registry record.

Talk to the study team

Mary V Gordon  ·  3017552752  ·  gordon@pire.org

Ted Miller, Ph.D.  ·  301-593-7471  ·  miller@pire.org

Always discuss trial participation with your own doctor first.

Locations (1)

HBSACalverton, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03262259